ABSTRACT
PURPOSE: Angioleiomyoma, predominantly arising from the extremities, is a benign soft tissue tumor. Reports on its intracranial location are rare. We assessed clinical, radiological, and pathological features of intracranial angioleiomyoma (iALM) treated at our neurosurgical institution. METHODS: We consecutively enrolled all patients with neuropathologically confirmed iALM treated at a single neurosurgical institution between 2013 and 2021. Clinical and imaging data were collected, and histological tissue sections were analyzed. A review of the literature on iALM was conducted. RESULTS: Seven patients with iALM (four female) with a median age of 45 years (range: 32-76 years) were identified. In three cases, the lesion was found incidentally. In magnetic resonance imaging (MRI), all tumors were hypo- to isointense on T1-weighted, hyperintense on T2-weighted sequences, and gadolinium-enhancing. A strong FLAIR signal was seen in six patients. Surgery consisted of gross total resection in all cases without perioperative complications. Neuropathological staining was positive for smooth muscle actin (SMA) in all lesions. Mature smooth muscle cells arranged around blood vessels were typically observed. The Ki-67 index was ≤ 3%. The patients were discharged after a median of 6 days (range: 4-9 days). During a median follow-up time of 14 months (range: 4-41 months), no tumor recurrence occurred. In the current literature, 42 additional cases of iALM were identified. CONCLUSION: Intracranial angioleiomyoma is a benign soft tissue tumor treated by gross total resection. Tumor morphology and positive staining for SMA lead to the neuropathological diagnosis.
Subject(s)
Angiomyoma , Brain Neoplasms , Humans , Angiomyoma/pathology , Angiomyoma/surgery , Angiomyoma/diagnostic imaging , Female , Middle Aged , Adult , Male , Aged , Brain Neoplasms/pathology , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/surgery , Magnetic Resonance ImagingABSTRACT
BACKGROUND: Intraoperative magnetic resonance imaging (io-MRI) improves the extent of glioma resection. Due to the magnetic field, patients have to be covered with sterile drape and are then transferred into an io-MRI chamber, where ferromagnetic anaesthesia monitors and machines must be kept at distance and can only be applied with limitations. Despite the development of specific paramagnetic equipment for io-MRI use, this method is suspected to carry a higher risk for anaesthesiological and surgical complications. Particularly, serial draping and un-draping cycles as well as the extended surgery duration might increase the risk of perioperative infection. OBJECTIVE: Given the importance of io-MRI for glioma surgery, the question regarding io-MRI safety needs to be answered. METHODS: We prospectively evaluate the perioperative anaesthesiological and surgical complications for 516 cases of brain tumour surgery involving io-MRI (MRI cohort). As a control group, we evaluate a cohort of 610 cases of brain tumour surgery, performed without io-MRI (control group). RESULTS: The io-MRI procedure (including draping/undraping, transfer to and from the MRI cabinet and io-MRI scan) significantly extended surgery, defined as "skin to skin" time, by 57 min (SD = 16 min) (p ≤ 0.01). Still, we show low and comparable rates of surgical complications in the MRI cohort and the control group. Postoperative haemorrhage (3.7% versus 3.0% in MRI cohort versus control group; p = 0.49) and infections (2.2% versus 1.8% in MRI cohort versus control group; p = 0.69) were not significantly different between both groups. No anaesthesiological disturbances were reported. CONCLUSION: Despite prolonged surgery and serial draping and un-draping cycles, io-MRI was not linked to higher rates of infections and postoperative haemorrhage in this study.
Subject(s)
Brain Neoplasms/surgery , Glioma/surgery , Magnetic Resonance Imaging , Neuronavigation , Neurosurgical Procedures , Adult , Aged , Aged, 80 and over , Brain Neoplasms/diagnostic imaging , Female , Glioma/diagnostic imaging , Humans , Intraoperative Complications/etiology , Magnetic Resonance Imaging/methods , Male , Middle Aged , Monitoring, Intraoperative/methods , Neuronavigation/methods , Neurosurgical Procedures/methods , Prospective Studies , Treatment OutcomeABSTRACT
BACKGROUND: The role of decompressive craniectomy (DC) in aneurysmal subarachnoid hemorrhage (aSAH) patients is still controversial. In this study we evaluated the effect of DC for aSAH patients. METHODS: A matched-pair analysis was performed to compare the outcomes of patients with DC to those of patients without DC. Among 295 consecutive aSAH patients, 56 required DC. Of the remaining group, 56 matched controls were found. The match was conducted on the basis of epidemiological and potential prognostic factors, such as age, gender, World Federation of Neurosurgical Societies (WFNS) grade, Fisher group and occurrence of vasospasm. RESULTS: Fifty-four of 56 (96.4%) patients with DC were dependent or dead at 1 month, compared with 49 of 56 (87.5%) without DC. There was no significant difference between the groups (p = 0.16). One-year outcomes were available for 108 patients (96.4%). Thirty-nine of 54 (72.2%) patients treated with DC were dependent or dead at 1 year, compared with 30 of 54 (55.6%) patients in the control group. There was no significant difference between the groups (p = 0.11). This result was unaffected by age, sex and WFNS grade. Subgroup analyses whether DC was performed primarily or delayed, and whether DC was performed due to spasm, hematoma or vessel occlusion failed to detect any significant difference. CONCLUSION: There was no significant advantage for patients treated with DC, but more than 25% achieved a good long-term outcome. While the value of DC is deemed uncertain, it may be effective for a very specific subset of aSAH patients. Further comparative studies are needed to resolve this matter.
Subject(s)
Decompressive Craniectomy , Intracranial Aneurysm/surgery , Subarachnoid Hemorrhage/surgery , Vasospasm, Intracranial/surgery , Adult , Aged , Decompressive Craniectomy/methods , Female , Humans , Intracranial Aneurysm/diagnosis , Male , Middle Aged , Retrospective Studies , Subarachnoid Hemorrhage/diagnosis , Treatment Outcome , Vasospasm, Intracranial/diagnosisABSTRACT
OBJECTIVE: Spinal intramedullary ependymomas (IEs) represent a well-defined tumor entity usually warranting resection. Factors that determine full long-term neurological recovery after resection are seldomly reported on in larger clinical series. In this study, the authors aimed to highlight the neurological outcome of patients with IEs after resection, with a focus on full neurological recovery, and to explore possible risk factors for the absence of neurological amelioration to an optimal function after surgical treatment. METHODS: A single-center retrospective analysis of all patients undergoing surgery for IEs between 2007 and 2021 was performed. Data collection included patient demographics, symptoms, clinical findings, histopathological diagnosis, surgical procedures, complications, and neurological outcome. Patients harboring a favorable outcome (modified McCormick Scale [mMS] grade of I) were compared with patients with a less favorable outcome (mMS grade ≥ II) at the final follow-up. RESULTS: In total, 72 patients with a histologically diagnosed IE were included. IEs in those patients (41 males, 31 females; median age 51 [IQR 40-59] years) mostly occurred in the cervical (n = 40, 56%) or thoracic (n = 23, 32%) spine. Upon admission, motor deficits or gait deficits (mMS grade ≥ II) were present in 29 patients (40%), with a median mMS grade of II (IQR I-II). Gross-total resection was achieved in 60 patients (90%), and the rate of surgical complications was 7%. Histopathologically, 67 tumors (93%) were classified as WHO grade 2 ependymomas, 3 (4%) as WHO grade 1 subependymomas, and 2 (3%) as WHO grade 3 anaplastic ependymomas. After a mean follow-up of 863 ± 479 days, 37 patients (51%) had a fully preserved neurological function and 62 patients (86%) demonstrated an mMS grade of I or II. Comparison of favorable with unfavorable outcomes revealed an association of early surgery (within a year after symptom onset), the absence of ataxia or gait disorders, and a low mMS grade with full neurological recovery at the final follow-up. A subgroup of patients (n = 15, 21%) had nonresolving deterioration at the final follow-up, with no significant differences in relevant variables compared with the rest of the cohort. CONCLUSIONS: The data presented solidify the role of early surgery in the management of spinal IEs, especially in patients with mild neurological deficits. Furthermore, the presence of gait disturbance or ataxia confers a higher risk of incomplete long-term recovery after spinal ependymoma resection. Because a distinct subgroup of patients had nonresolving deterioration, even when presenting with an uneventful history, further analyses into this subgroup of patients are required.
Subject(s)
Ependymoma , Spinal Cord Neoplasms , Male , Female , Humans , Middle Aged , Neurosurgical Procedures/methods , Retrospective Studies , Spinal Cord Neoplasms/pathology , Ataxia/complications , Ataxia/surgery , Ependymoma/diagnosis , Treatment OutcomeABSTRACT
OBJECTIVE: Cerebellar mutism syndrome (CMS) is a well-known complication after posterior fossa tumor surgery in pediatric patients. We evaluated the incidence of CMS in our institute and analyzed its association with multiple risk factors, such as tumor entity, surgical approach, and hydrocephalus. METHODS: All pediatric patients who had undergone intra-axial tumor resection in the posterior fossa between January 2010 and March 2021 were included in the retrospective analysis. Various data points, including demographic, tumor-associated, clinical, radiological, surgery-associated, complications, and follow-up data, were collected and statistically evaluated for an association with CMS. RESULTS: A total of 63 surgeries in 60 patients were included. The median patient age was 8 years. Pilocytic astrocytoma was the most common tumor type (50%), followed by medulloblastoma (28%) and ependymomas (10%). Complete, subtotal, and partial resection was achieved in 67%, 23%, and 10%, respectively. A telovelar approach had been used the most often (43%) compared with a transvermian approach (8%). Of the 60 children, 10 (17%) had developed CMS and showed marked improvement but with residual deficits. The significant risk factors were a transvermian approach (P = 0.03), vermian splitting when added to another approach (P = 0.002), an initial presentation with acute hydrocephalus (P = 0.02), and hydrocephalus present after tumor surgery (P = 0.004). CONCLUSIONS: Our CMS rate is comparable to those described in the literature. Despite the limitations of the retrospective study design, we found that CMS was not only associated with a transvermian approach but was also associated with a telovelar approach, although to a lesser extent. Acute hydrocephalus at the initial presentation necessitating urgent management was significantly associated with a greater incidence of CMS.
Subject(s)
Brain Neoplasms , Cerebellar Diseases , Cerebellar Neoplasms , Hydrocephalus , Infratentorial Neoplasms , Medulloblastoma , Mutism , Child , Humans , Retrospective Studies , Mutism/epidemiology , Mutism/etiology , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Brain Neoplasms/surgery , Cerebellar Diseases/etiology , Medulloblastoma/complications , Infratentorial Neoplasms/surgery , Infratentorial Neoplasms/complications , Hydrocephalus/epidemiology , Hydrocephalus/etiology , Hydrocephalus/surgery , Cerebellar Neoplasms/surgery , Cerebellar Neoplasms/complicationsABSTRACT
A major complication of aneurysmal subarachnoid hemorrhage (SAH) is symptomatic vasospasm, a complex syndrome consisting of neurological deterioration and exclusion of other sources of ischemia. Approximately 30% of SAH patients are affected. Although symptomatic vasospasm is associated with high mortality and poor clinical outcome, it is not possible to identify the individual risk on a molecular level for patients before symptoms have developed. In this study, we hypothesize that protein changes occur in the cerebral microdialysate of patients who later develop symptomatic vasospasm which are not found in matched-pairs control subjects. We searched for changes in protein concentrations in microdialysate sampled from the fronto-temporal brain tissue of five vasospastic and five nonvasospastic SAH patients using proteomics technology based on two-dimensional gel electrophoresis and mass spectrometry. Microdialysate samples were taken at least 1.5 days before the onset of symptomatic vasospasm. Comparing protein expression profiles, we found that the protein concentrations of several isoforms of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 1.79-fold+/-1.29 (N=5, P<0.05) higher in the group which later developed symptomatic vasospasm, whereas heat-shock cognate 71 kDa protein (HSP7C) isoforms were decreased to 0.50-fold+/-0.19 (N=5, P<0.05; all expression data means+/-s.d.). The changes in protein concentrations were detected 3.8+/-1.7 days (N=5, P<0.05) before symptomatic vasospasm developed. We conclude that GAPDH and HSP7C may be used as early markers indicating the later development of symptomatic vasospasm after SAH, enabling selective early therapeutic intervention in this high-risk group of patients.
Subject(s)
Proteome/metabolism , Subarachnoid Hemorrhage/metabolism , Subarachnoid Hemorrhage/pathology , Vasospasm, Intracranial/metabolism , Vasospasm, Intracranial/pathology , Adult , Biomarkers/analysis , Electrophoresis, Gel, Two-Dimensional , Female , Humans , Male , Microdialysis , Middle Aged , Protein Array Analysis , Protein Isoforms/metabolism , Time FactorsABSTRACT
OBJECTIVE: Hyperglycemia after aneurysmal subarachnoid hemorrhage (SAH) is associated with serious complications. Blood glucose may indicate a target for therapy to prevent delayed ischemic neurological deficits (DIND) and improve outcome. The objective of this study was to investigate energy metabolism in the extracellular/cerebrospinal fluid and blood in relation to outcome. METHODS: Prospective non-randomized study was carried out in the intensive care unit (ICU) of university hospital (n = 170 aneurysmal SAH patients, age: 51.0 +/- 12.6 years old). Following approval by the ethics committee, a microdialysis catheter was inserted into the vascular territory of the aneurysm after clipping. Patients were studied for 165 +/- 84 hours and classified according to the presence of neurological symptoms as asymptomatic (n = 66) and symptomatic (n = 104): acute focal neurological deficits (AFND, n = 61) and delayed ischemic neurological deficits (DIND, n = 43). The microdialysates were analysed hourly for energy metabolites. Daily morning blood glucose and cerebrospinal fluid (CSF) levels (glucose and lactate) were determined. Six-month Glasgow outcome scale (GOS) was assessed. RESULTS: Hyperglycemia on admission and high blood glucose levels on the following days were significantly related to the presence of symptoms, most pronounced in patients with poor outcome (p<0.05). In symptomatic patients (high blood glucose), the lowest extracellular fluid (ECF) glucose concentrations were found, most pronounced in the AFND group (1.0 +/- 1.2 mmol/l). The anaerobic metabolites lactate, lactate/pyruvate ratio (LPR) and lactate/glucose ratio (LGR) were higher in symptomatic patients (p<0.001) indicating cerebral metabolic distress. CSF concentrations of glucose and lactate were of no specific value. CONCLUSION: This study confirms the relevance of hyperglycemia to neurological outcome in SAH patients. Cerebral glucose was significantly lower in AFND patients despite hyperglycemic blood levels. More detailed works are necessary to select risk patients for optimized targeted therapy to avoid insulin-induced cerebral metabolic crisis.
Subject(s)
Blood Glucose/metabolism , Energy Metabolism , Glucose/cerebrospinal fluid , Hyperglycemia/physiopathology , Subarachnoid Hemorrhage/complications , Adult , Brain/blood supply , Brain/metabolism , Brain/physiopathology , Extracellular Fluid/metabolism , Female , Glycolysis , Humans , Hyperglycemia/etiology , Hyperglycemia/metabolism , Lactic Acid/blood , Male , Microdialysis , Middle Aged , Predictive Value of Tests , Prospective Studies , Pyruvic Acid/cerebrospinal fluidABSTRACT
Functional magnetic resonance imaging (fMRI) is currently combined with electrophysiological methods to identify the relationship between neuronal activity and the blood oxygenation level-dependent (BOLD) signal. Several processes like neuronal activity, synaptic activity, vascular dilation, blood volume and oxygenation changes underlie both response modalities, that is, the electrophysiological signal and the vascular response. However, accessing single process relationships is absolutely mandatory when aiming at a deeper understanding of neurovascular coupling and necessitates studies on the individual building blocks of the vascular response. Combined fMRI and functional near-infrared spectroscopy studies have been performed to validate the correlation of the BOLD signal to the hemodynamic changes in the brain. Here we review the current status of the integration of both technologies and judge these studies in the light of recent findings on neurovascular coupling.
Subject(s)
Cerebrovascular Circulation/physiology , Magnetic Resonance Imaging/statistics & numerical data , Oxygen/blood , Signal Transduction/physiology , Spectroscopy, Near-Infrared/statistics & numerical data , Blood Volume , Brain/blood supply , Humans , Magnetic Resonance Imaging/methods , Spectroscopy, Near-Infrared/methodsABSTRACT
Intravenous administration of thrombolytic agents is considered to be contraindicated in patients with intracranial neoplasms. However, only a single case of thrombolysis-related intracranial tumour haemorrhage has been reported to our knowledge and several studies have suggested that systemic thrombolysis can be safely carried out in these patients. Here we report a patient who developed haemorrhage into a previously unknown intracranial tumour following intravenous thrombolysis for acute myocardial ST-elevation infarction. Identification of abnormal tissue during surgical haematoma evacuation initiated histopathological examination which revealed meningioma World Health Organization Grade I. Intracranial tumours may represent the causative pathology in cases of thrombolysis-related intracranial haemorrhage and this should be considered in the treatment of these patients.
Subject(s)
Intracranial Hemorrhages/chemically induced , Intracranial Hemorrhages/diagnosis , Meningeal Neoplasms/diagnosis , Meningioma/diagnosis , Thrombolytic Therapy/adverse effects , Fibrinolytic Agents/adverse effects , Humans , Infusions, Intravenous , Male , Meningeal Neoplasms/complications , Meningioma/complications , Middle AgedABSTRACT
BACKGROUND: Disturbed brain metabolism is a signature of primary damage and/or precipitates secondary injury processes after severe brain injury. Sedatives and analgesics target electrophysiological functioning and are as such well-known modulators of brain energy metabolism. Still unclear, however, is how sedatives impact glucose metabolism and whether they differentially influence brain metabolism in normally active, healthy brain and critically impaired, injured brain. We therefore examined and compared the effects of anesthetic drugs under both critical (<1 mmol/L) and noncritical (>1 mmol/L) extracellular brain glucose levels. METHODS: We performed an explorative, retrospective analysis of anesthetic drug administration and brain glucose concentrations, obtained by bedside microdialysis, in 19 brain-injured patients. RESULT: Our investigations revealed an inverse linear correlation between brain glucose and both the concentration of extracellular glutamate (Pearson r=-0.58, P=0.01) and the lactate/glucose ratio (Pearson r=-0.55, P=0.01). For noncritical brain glucose levels, we observed a positive linear correlation between midazolam dose and brain glucose (P<0.05). For critical brain glucose levels, extracellular brain glucose was unaffected by any type of sedative. CONCLUSIONS: These findings suggest that the use of anesthetic drugs may be of limited value in attempts to influence brain glucose metabolism in injured brain tissue.
Subject(s)
Brain Injuries/metabolism , Brain/drug effects , Brain/metabolism , Glucose/metabolism , Hypnotics and Sedatives/pharmacology , Microdialysis/methods , Adult , Aged , Dose-Response Relationship, Drug , Female , Glutamic Acid/metabolism , Humans , Lactic Acid/metabolism , Male , Midazolam/pharmacology , Middle Aged , Retrospective StudiesABSTRACT
BACKGROUND AND PURPOSE: Cerebral microdialysis (MD) is discussed as a technique for detection of cerebral ischemia in subarachnoid hemorrhage; however, clinical data on cerebral blood flow (CBF) are limited in these patients. The main objective of this study was to investigate whether pathological MD parameters reflect a reduced regional CBF (rCBF) determined by 15O-H2O PET. METHODS: Thirteen subarachnoid hemorrhage patients (age, 48.7+/-15.0 years; World Federation of Neurological Surgeons grade 1 to 5) were studied. Extracellular glucose, lactate, lactate/pyruvate (L/P) ratio, glutamate, and glycerol levels were analyzed hourly. rCBF was determined in the volume of interest of the MD catheter and all vascular territories. MD values were correlated to rCBF on the day of PET. Then, MD concentrations of asymptomatic versus ischemic phases (3-day medians) were analyzed. RESULTS: In symptomatic patients (n=10), rCBF was significantly lower compared with controls (n=3, P=0.048). Glutamate correlated best with rCBF (r=-0.66; P=0.014), followed by glycerol (r=-0.62; P=0.021). The L/P ratio was most sensitive (0.82) and specific (1.0) in indicating symptoms of ischemia, but only during longer periods of ischemia. CONCLUSIONS: rCBF correlates best with glutamate, followed by glycerol, whereas the L/P ratio is sensitive only after longer periods of ischemia. Clinically relevant regional metabolic derangements occur already above an rCBF of 20 mL x 100 g(-1).min(-1). Future research should focus on identifying alternative causes of metabolic derangement in subarachnoid hemorrhage patients and optimal treatment management in these patients.
Subject(s)
Brain Ischemia/diagnosis , Brain/blood supply , Brain/metabolism , Cerebrovascular Circulation , Microdialysis/statistics & numerical data , Subarachnoid Hemorrhage/diagnosis , Adult , Aged , Biomarkers/analysis , Blood Flow Velocity , Brain Ischemia/diagnostic imaging , Brain Ischemia/etiology , Extracellular Fluid/chemistry , Extracellular Fluid/metabolism , Female , Glucose/analysis , Glutamic Acid/analysis , Glycerol/analysis , Humans , Lactic Acid/analysis , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Pyruvic Acid/analysis , Sensitivity and Specificity , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/physiopathology , Tomography, Emission-Computed , Vasospasm, Intracranial/complications , Vasospasm, Intracranial/diagnosisABSTRACT
BACKGROUND AND PURPOSE: We sought (1) to identify early metabolic markers for the development of (ir)reversible neurological deficits and cerebral infarction in subarachnoid hemorrhage (SAH) patients by using the microdialysis technique and (2) to evaluate the influence of intracerebral hemorrhage (ICH) on microdialysis parameters. METHODS: We performed a prospective study of 44 SAH patients with acute focal neurological deficits (AFND) occurring acutely with SAH (due to ICH) or directly after surgery (due to clip stenosis, thromboembolism, or early edema). Fifty-one nonischemic SAH patients served as a control group. A microdialysis catheter was inserted into the vascular territory of the aneurysm after clipping. The microdialysates were analyzed hourly for extracellular glucose, lactate, lactate/pyruvate ratio, glutamate, and glycerol with a bedside analyzer. Microdialysis-related CT findings were evaluated for the presence of ICH and cerebral infarction. Reversibility of neurological symptoms after 4 weeks and 6- and 12-month outcomes were assessed. RESULTS: In patients with AFND, cerebral metabolism was severely disturbed when microdialysis started compared with controls (P<0.005). Infarction on CT was associated with pathological microdialysis parameters (P<0.002) and development of a fixed deficit (P<0.003), while the presence of ICH alone was not. A secondary neurological deterioration of AFND patients (n=11) was reflected by preceding (0 to 20 hours) changes of microdialysate concentrations. CONCLUSIONS: In the presence of ICH, pathological microdialysis values may indicate reversible tissue damage. Extreme microdialysis values and pathological microdialysis concentrations that further deteriorate 2-fold are highly indicative of the development of cerebral infarction and permanent neurological deficits. Therefore, the analysis of relative changes of microdialysis parameters is crucial for the detection of ischemia in SAH patients.
Subject(s)
Nervous System Diseases/diagnosis , Nervous System Diseases/physiopathology , Subarachnoid Hemorrhage/diagnosis , Subarachnoid Hemorrhage/physiopathology , Acute Disease , Biomarkers/analysis , Brain/blood supply , Brain/diagnostic imaging , Brain/physiopathology , Cerebral Angiography , Demography , Disease Progression , Female , Glucose/analysis , Glutamic Acid/analysis , Glycerol/analysis , Humans , Lactose/analysis , Male , Microdialysis , Middle Aged , Monitoring, Physiologic , Nervous System Diseases/complications , Paresis/etiology , Predictive Value of Tests , Prospective Studies , Subarachnoid Hemorrhage/complications , Tomography, X-Ray Computed , Vasospasm, Intracranial/etiologyABSTRACT
OBJECT: The majority of patients with poor-grade subarachnoid hemorrhage (SAH), that is, World Federation of Neurosurgical Societies (WFNS) Grades IV and V, have high morbidity and mortality rates. The objective of this study was to investigate cerebral metabolism in patients with low- compared with high-grade SAH by using bedside microdialysis and to evaluate whether microdialysis parameters are of prognostic value for outcome in SAH. METHODS: A prospective investigation was conducted in 149 patients with SAH (mean age 50.9 +/- 12.9 years); these patients were studied for 162 +/- 84 hours (mean +/- standard deviation). Lesions were classified as low-grade SAH (WFNS Grades I-III, 89 patients) and high-grade SAH (WFNS Grade IV or V, 60 patients). After approval by the local ethics committee and consent from the patient or next of kin, a microdialysis catheter was inserted into the vascular territory of the aneurysm after clip placement. The microdialysates were analyzed hourly for extracellular glucose, lactate, lactate/pyruvate (L/P) ratio, glutamate, and glycerol. The 6- and 12-month outcomes according to the Glasgow Outcome Scale and functional disability according to the modified Rankin Scale were assessed. In patients with high-grade SAH, cerebral metabolism was severely deranged compared with those who suffered low-grade SAH, with high levels (p < 0.05) of lactate, a high L/P ratio, high levels of glycerol, and, although not significant, of glutamate. Univariate analysis revealed a relationship among hyperglycemia on admission, Fisher grade, and 12-month outcome (p < 0.005). In a multivariate regression analysis performed in 131 patients, the authors identified four independent predictors of poor outcome at 12 months, in the following order of significance: WFNS grade, patient age, L/P ratio, and glutamate (p < 0.03). CONCLUSIONS: Microdialysis parameters reflected the severity of SAH. The L/P ratio was the best metabolic independent prognostic marker of 12-month outcome. A better understanding of the causes of deranged cerebral metabolism may allow the discovery of therapeutic options to improve the prognosis, especially in patients with high-grade SAH, in the future.
Subject(s)
Brain/metabolism , Brain/surgery , Intracranial Aneurysm/complications , Intracranial Aneurysm/surgery , Microdialysis/methods , Point-of-Care Systems , Subarachnoid Hemorrhage , Disability Evaluation , Female , Glasgow Coma Scale , Glucose/metabolism , Glutamic Acid/metabolism , Humans , Hyperglycemia/diagnosis , Lactic Acid/metabolism , Male , Middle Aged , Neurosurgical Procedures/methods , Prospective Studies , Pyruvic Acid/metabolism , Subarachnoid Hemorrhage/diagnosis , Subarachnoid Hemorrhage/etiology , Subarachnoid Hemorrhage/surgery , Treatment OutcomeABSTRACT
Cerebral microdialysis is applied in clinical neurology and neurosurgery as monitoring tool in patients to evaluate the progression of severe diseases, such as stroke or trauma. Besides small molecules, e.g. metabolites and neurotransmitters, also the macromolecules, such as proteins and larger chemical compounds cross the dialysis membrane of the catheters implanted into the human brain parenchyma. Microdialysis can be used to extract molecules from the extracellular space of the brain in vivo, but additionally to deliver drugs, since the exchange is dependent on concentration gradients. Cerebral microdialysis may also be useful in the prediction of the clinical onset of symptoms, based on changes in the composition of pre-symptomatic microdialysate. For example, symptomatic vasospasm, which is a complication after subarachnoid hemorrhage, may be predicted by the combination of cerebral microdialysis and a proteomics approach. We will introduce the basic concepts of cerebral microdialysis, discuss possible clinical applications, and evaluate the application of proteomic approaches. With regard to technological aspects, we describe two-dimensional gel electrophoresis, high-pressure liquid chromatography, and mass spectrometry. With regard to clinical aspects, we discuss ethics, feasibility, time-course, and therapeutic options. In conclusion, proteomics of cerebral microdialysate may be used for diagnosis, disease monitoring, and therapeutic intervention of neurological patients.